Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TU 100

Next Previous
X
Search
Drug Profile

TU 100

Alternative Names: Dai-kencho-to; Dai-kenchu-to; TJ-100; TU-100

Latest Information Update: 27 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tsumura
  • Class Anti-inflammatories; Herbal medicines; Irritable bowel syndrome therapies; Laxatives
  • Mechanism of Action Acetylcholine stimulants; Motilin stimulants; Serotonin 3 receptor agonists; Serotonin 4 receptor agonists; Substance P stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Irritable bowel syndrome; Postoperative ileus
  • Phase II Constipation; Crohn's disease
  • No development reported Inflammatory bowel diseases

Most Recent Events

  • 27 Nov 2024 No development reported - Phase-III for Inflammatory bowel diseases in Japan (PO)
  • 01 May 2024 Tsumara completes a phase II trial for Postoperative ileus in USA (NCT04742907)
  • 29 Jul 2021 Tsumara initiates a phase II trial for Postoperative ileus in USA (NCT04742907)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top